Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is experiencing impressive recent technology transfer wins which are expected to have a significant impact on their financials in the long term. The company's continued execution of its strategic vision, driven by CEO Paul Josephs and his team, has led to a broader business scope and potential for growth. With a 20x multiple applied to their adjusted EBITDA and accounting for potential risks, we have arrived at an OUTPERFORM rating and a 12-month price target of $6.50.

Bears say

Lifecore Biomedical is in the execution phase of its turnaround story led by CEO Paul Josephs, with significant progress being made in terms of new business wins and expense management. The recent hire of Amber Shook as Head of Business Transformation suggests a focus on becoming more efficient. However, the company's high level of leverage and low cash position may raise concerns about its ability to sustain growth and meet its longer-term targets.

LFCR has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 1 analysts, LFCR has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.